Safinamide D3

Safinamide D3 is a deuterated form of safinamide, a drug used to treat Parkinson's disease. This medication acts as a selective and reversible inhibitor of monoamine oxidase type B (MAO-B), an enzyme that breaks down dopamine in the brain. By inhibiting the activity of MAO-B, safinamide D3 helps to increase the levels of dopamine in the brain, which can improve the symptoms of Parkinson's disease, such as tremors, stiffness, and slow movement. Safinamide D3 is administered orally as a tablet, typically in doses of 50 to 100 mg once daily. It is absorbed quickly and reaches peak plasma concentrations within 2 to 4 hours. The drug is metabolized in the liver and eliminated primarily in the urine. Safinamide D3 has a chemical formula of C15H14D3ClN2O2 and a molecular weight of 282.76 g/mol. It is a white to off-white crystalline powder that is sparingly soluble in water. The deuterated form of safinamide is used in clinical studies to evaluate the pharmacokinetics and metabolism of the drug, as well as its efficacy and safety in treating Parkinson's disease. While safinamide D3 is generally well-tolerated, it can cause side effects such as nausea, dizziness, insomnia, and abnormal dreams. It may also interact with other medications, including antidepressants, antipsychotics, and certain antibiotics. Patients should consult with their healthcare provider before taking safinamide D3 to ensure the drug is appropriate for their condition and medical history.